Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Landscape of copy number variants in Spanish people with dementia.

NPJ genomic medicine·2026
Same author

Listening for Alzheimer's clues: machine learning analysis of multidomain speech features for cognitive impairment screening.

Frontiers in aging neuroscience·2026
Same author

Non-linear associations between sleep duration and plasma p-tau181 in the Framingham Heart Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease.

Science translational medicine·2026
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026
Same author

Unveiling pathogens and contaminants: refining metagenomics for clinical diagnostics.

Frontiers in microbiology·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Maria Capdevila1, Raquel Puerta1, Laura Montrreal1

  • 1Ace Alzheimer Center Barcelona, Barcelona, Spain.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Plasma pTau217 shows promise as a screening tool for Alzheimer's disease (AD) risk, outperforming pTau181 in preclinical stages. Further validation is needed before widespread clinical adoption.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • The advent of Disease Modifying Drugs for Alzheimer's disease (AD) necessitates reliable diagnostic tools.
  • Plasma biomarkers are emerging as a practical solution for AD risk assessment in clinical settings.

Purpose of the Study:

  • To evaluate the efficacy of plasma pTau217 as a screening tool for AD risk in a real-world memory clinic setting.
  • To compare the performance of plasma pTau217 against plasma pTau181 and established diagnostic methods.

Main Methods:

  • Analysis of 2353 paired cerebrospinal fluid (CSF) and plasma samples from patients with cognitive decline.
  • Measurement of plasma pTau181 and pTau217 using the Lumipulse G1200 platform.
  • Statistical analysis including ROC curves, correlation, and survival analysis.

Main Results:

  • Plasma pTau217 strongly correlated with CSF biomarkers and showed high diagnostic accuracy (AUC=0.97).
  • Plasma pTau217 demonstrated superior performance over pTau181 in preclinical AD stages.
  • Plasma pTau217 levels correlated with AD-related brain changes on MRI and predicted MCI to AD dementia conversion.

Conclusions:

  • Plasma pTau217 is a robust biomarker for screening AD risk, particularly in preclinical stages.
  • While promising, plasma biomarkers require further validation and are not yet standalone diagnostic tests.
  • Continued research is essential to refine plasma biomarkers for eventual replacement of CSF/PET diagnostics.